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ABSTRACT
Idiopathic pneumonia syndrome (IPS) is a frequently fatal complication following allogeneic stem cell transplan-
tation (allo-SCT). Experimental models have revealed that TNF-a contributes to pulmonary vascular endothelial
cell (EC) apoptosis, and modulates the infiltration of donor leukocytes into the lung parenchyma. The inflamma-
tory effects of TNF-a aremediated by signaling through the type I (TNFRI) or type II (TNFRII) TNF receptors.
We investigated the relative contribution of TNFRI and TNFRII to leukocyte infiltration into the lung following
allo-SCT by using establishedmurinemodels.Wild-type (wt) B6mice or B6 animals deficient in either TNFRI or
TNFRIIwere lethally irradiated and received SCT from allogeneic (LP/J) or syngeneic (B6) donors. Atweek 5 fol-
lowing SCT, the severity of IPS was significantly reduced in TNFRII2/2 recipients compared to wt controls, but
no effectwas observed inTNFRI2/2 animals.Bronchoalveolar lavagefluid (BALF) levels ofRANTESandpulmo-
nary ICAM-1 expression in TNFRII2/2 recipients were also reduced, and correlated with a reduction of CD81
cells in the lung. Pulmonary inflammation was also decreased in TNFRII2/2mice using an isolatedMHC class I
disparatemodel (bm1/B6), and inbm1wtmice transplantedwithB6TNF-a2/2 donor cells. Collectively, these
data demonstrate a role forTNF-a signaling throughTNFRII in leukocyte infiltration into the lung following allo-
SCT, and suggest that disruption of the TNF-a:TNFRII pathwaymay be an effective tool to prevent or treat IPS.
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Pulmonary dysfunction is a major complication
following allogeneic stem cell transplantation (allo-
SCT) [1-4]. Idiopathic pneumonia syndrome (IPS)
has been defined as diffuse, noninfectious lung injurythat occurs within 4 months of SCT [1]. Although
recent studies have reported a lower incidence (5%-
10%) and an earlier time to onset of IPS than originally
described, the typical clinical course involving the
rapid onset of pulmonary failure resulting in death385
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ture of this complication [3,5,6]. Risk factors for IPS
include myeloablative versus nonmyeloablative condi-
tioning regimens, the use of total-body irradiation
(TBI), the development of acute graft-versus-host dis-
ease (GVHD), and older recipient age [2,3,6-9], but
the pathophysiology of this disorder remains enig-
matic. Data generated from experimental models
suggest that the lung is vulnerable to a two-pronged
immunologic attack after allo-SCT, involving both al-
loantigen-specific donor T cell responses [10-13] and
the production of inflammatory cytokines [11,14-18].
With respect to the latter, previous work has uncov-
ered a causal relationship between TNF-a and IPS
[14,15,19]; hyporesponsiveness of donor cells to lipo-
polysaccharide (LPS) stimulation [15] and the neutral-
ization of TNF-a [14] result in decreased lung injury
after SCT. Moreover, we have recently shown that
TNF-a contributes to pulmonary vascular apoptosis
and regulates pulmonary chemokine expression and
the subsequent recruitment of inflammatory cells to
the lung of allo-SCT recipients [20].
The actions of TNF-a are mediated by 2 recep-
tors: a 55- to 60-kDa type I receptor (TNFRI; p55/60;
CD120a) and a 75- to 80-kDa type II receptor
(TNFRII; p75/80; CD120b) [21-24]. These 2 recep-
tors are coexpressed in almost every cell in the body,
but in contrast to the constitutive expression of
TNFRI, the expression of TNFRII is strongly modu-
lated by various cytokines including TNF-a, IL-1,
IFN-g, and inflammatory stimuli like LPS [25-27].
In addition, both receptors can be released into the
blood following proteolysis where they function as
molecules capable of binding circulating TNF-
a [28,29]. TNFRI is generally regarded as the domi-
nant receptor in TNF-a biology; it is the high-affinity
receptor for soluble TNF-a (sTNF-a), and mediates
many of the pro-inflammatory effects of this cytokine
[30-34]. TNFRI deficiency or TNFRI blockade by us-
ing p55-specific monoclonal antibodies (mAbs) results
in resistance to endotoxic shock, but enhances suscep-
tibility to infection with certain bacteria such as Liste-
ria monocytogenes [33,35,36]. A role for TNFRI has
been described in eliciting fulminant alloreactive T
cell responses [37,38] and in the inflammatory envi-
ronment that characterizes acute GVHD (aGVHD)
early after allo-SCT [39,40]. TNFRI also contributes
to the development of acute lung injury during
hemorrhagic shock [41].
The absence of TNFRII significantly reduces the
dermatotoxic and lethal effects of TNF-a [42], and
mAbs specific for either TNFRI or TNFRII block
the development of TNF-a-induced skin necrosis in
mice [36]. TNFRII expression is increased on micro-
vascular endothelial cells (ECs) in the lung during
adult respiratory distress syndrome (ARDS), and is as-
sociated with the enhanced expression of cell adhesionmolecules including ICAM-1, VCAM-1, and of CD14
in this context [43,44]. Animals deficient in both
TNFRI and TNFRII are protected against the effects
of TNF-a as a central mediator in bleomycin-induced
pulmonary fibrosis [45] and develop delayed pulmo-
nary injury after the infusion of alloreactive T helper
1 (Th1) cells [19].
Given the previously identified role for TNF-a in
leukocyte infiltration into the lung during the
development of IPS, we sought to determine the rela-
tive contributions of TNFRI and TNFRII to the
inflammation engendered in this context by using
well-established mouse SCT models [12,16,46]. Alter-
ations in histopathology, lung function, pulmonary
vascular EC integrity, and the cellular and cytokine
content of bronchoalveolar lavage fluid (BALF) ob-
served in these models correlate very well with that
seen in patients with IPS [1,12,20,46-50]. Importantly,
mechanistic insights provided by these experimental
systems are actively being translated back to the clinic
in the form of novel treatment strategies for this com-
plication [5]. Our results show that TNF-a signaling
through TNFRII plays a significant role in leukocyte
infiltration to the lung during IPS. BALF levels of
the inflammatory chemokine RANTES (CCL5) and
the pulmonary expression of ICAM-1 were also re-
duced in TNFRII2/2 recipients and correlated with
decreases in CD81 cells in the lung. Finally, the reduc-
tion in lung inflammation present in TNFRII2/2 re-
cipients is comparable to that observed when wild-type
(wt) mice are transplanted with allogeneic TNF-a-de-
ficient donor cells, thereby strengthening the role of
TNF-a:TNFRII interactions in the pathophysiology
of IPS.
MATERIALS AND METHODS
Mice and Bone Marrow Transplantation
Female C57BL/6 (H-2b), LP/J (H-2b), B6.C-
H2bm1/ByJ (H-2b), B6.129-Tnfrsf1atm1Mak/J (H-2b;
TNFRI2/2, p55 deficient) [33], B6.129S2-
Tnfrsf1btm1Mwm/J (H-2b; TNFRII2/2, p75 deficient)
[42], B6129SF2/J (H-2b; TNF-a1/1), and
B6;129S6-Tnftm1Gkl (H-2b; TNF-a2/2) [51] were
purchased from the Jackson Laboratories (Jax, Bar
Harbor, ME) or from the Frederick Cancer Research
and Development Center (National Cancer Institute,
Frederick, MD). Animals used for SCT and in vitro
experiments were between 10 and 14 weeks old. All
experiments were approved by the University of Mich-
igan Committee on the Use and Care of Animals
(UCUCA).
Mice were transplanted according to a standard
protocol as described previously [50]. When using
the MHC matched, minor histocompatibility complex
disparate LP/J/ B6 system, B6 wt, B6 TNFRI2/2
and B6 TNFRII2/2 recipients received 13 Gy of
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bone marrow (BM) cells and 2  106 splenic T cells
from either syngeneic (B6) or allogeneic LP/J mice.
T cell purification was performed by magnetic bead
separation using CD4 and CD8 MicroBeads and the
autoMACS system (Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany) according to the manufacturer’s
protocol with .85% of cells obtained being positive
for CD4 or CD8 surface antigens (data not shown).
Percentages of purified CD41 and CD81 T cells did
not significantly differ between donors. Transplanted
mice were cared for as previously described [52].
In experiments using the B6/ bm1 or bm1/ B6
SCT systems (isolated MHC I-mismatch), host mice
received 11 Gy TBI followed by the infusion of 5 106
BM and 1.8-2.0  106 autoMACS-purified (.85%
purity) CD81 T cells. These changes in transplant
parameters were made to ensure that sufficient animals
would be available for analysis at time points when
significant lung injury is present.
Clinical GVHD, Survival, and Semiquantitative
Evaluation of Lung Histopathology
Survival was monitored daily, and GVHD clinical
scores were assessed weekly by a scoring system incor-
porating 5 clinical parameters: weight loss, posture
(hunching), mobility, fur texture, and skin integrity
as described [46]. Pulmonary toxicity after SCT was
determined by examination of lung histopathology in
transplanted animals as previously described [46].
Lung sections from individual mice were stained,
coded without reference to mouse type or prior treat-
ment regimen, and examined by C.L. to establish an
index of injury. Lung tissue was evaluated for the pres-
ence of periluminal infiltrates (around airways and ves-
sels) or parenchymal pneumonitis (involving the
alveoli or interstitium) using a semiquantitative scor-
ing system that evaluates both the severity and extent
of histopathology present [46].
BAL
At the time of analysis, mice were sacrificed by ex-
sanguination and BAL was performed as previously
described [46]. After centrifugation, supernatants
were frozen for subsequent analysis of cytokine and
chemokine content, and cell pellets were washed and
counted. In some experiments, aliquots of cell suspen-
sions were stained with fluorescent antibodies to cell
surface antigens and analyzed by FACS analysis.
Cell Surface Phenotype Analysis
To analyze cell surface phenotype, cells were
stained with fluorescein isothiocyanate (FITC) conju-
gated mAbs to Ly9.1 and CD8 or with phycoerythrin
(PE) conjugated mAbs to CD4 and CD8 for flow cyto-metric analysis as previously described [15]. Two-
color flow cytometric analysis of 1  104 cells was
performed using a FACSCalibur (BD Biosciences,
San Jose, CA).
Measurement of Cytokine and Chemokine Protein
Levels by ELISA
Concentrations of specific cytokines and chemo-
kines were measured in the BALF using ELISA kits
from BioSource (Camarillo, CA) for TNFa (Bio-
Source #KMC 3012) and MCP-1/CCL2 (BioSource
#KMC 1012), and from Quanitkine M, R&D Systems
(Minneapolis, MN) for RANTES/CCL5 and MIP-
1b/CCL3. Assays were performed according to the
manufacturer’s protocol. Assay sensitivity was \3.0
pg/mL for TNF-a,\2.0 pg/mL for RANTES,\1.5
pg/mL for MIP-1a, and\9 pg/mL for MCP-1.
Immunohistochemical Detection of ICAM-1
Immunohistochemical staining was performed on
lung tissue 5 weeks after transplant with goat-anti-
mouse CD54/ICAM-1 antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA) or Goat-IgG isotype control
(Sigma-Aldrich, St. Louis, MO) (both 1:200 dilution)
and the VECTASTAIN Elite ABC peroxidase immu-
nostaining kit (Vector Laboratories, Burlingame, CA)
plus DAB substrate (Vector Laboratories) according to
the manufacturer’s protocol. Slides were counter-
stained with Hematoxylin QS (Vector Laboratories)
and analyzed by light microscopy (Olympus IX71 in-
verted research microscope; Olympus Corporation,
Tokyo, Japan). Photomicrographs were acquired
with the OlympusDP controller (Olympus Corpora-
tion) and processed with Adobe Photoshop (Adobe,
San Jose, CA).
Real-Time RT-PCR Analysis
After perfusion of the pulmonary vascular system
with ice-cold PBS, whole-lung tissue was retrieved at
various time points after SCT and stored at 280C.
mRNA was extracted from whole lungs using TRIzol
following the manufacturer’s protocol (GibcoBRL,
Grand Island, NY) and quantitated by spectrophotom-
etry. ICAM-1 and GAPDH (an internal control)
expression were analyzed by real-time RT-PCR pro-
cedure using an ABI Prism 7000 sequence detection
system (Applied Biosystems, Foster City, CA). All
primers and probes used were purchased from Applied
Biosystems. ICAM-1 expression was normalized to
GAPDH before the fold change in ICAM-1 expression
was calculated by comparing values obtained from in-
dividual wt or TNFRII2/2 allo-SCT recipients to the
average value measured in syngeneic controls. To this
end, ICAM-1 expression in syngeneic mice was given
an arbitrary value of 1.
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All values are expressed as the mean 6 SEM. Sta-
tistical comparisons between groups were completed
using the parametric independent sample t-test when
appropriate or the Mann-Whitney test if there were
\5 animals per group or if data did not meet the
assumptions of normal distribution and equal variance
required for a t-test. The Wilcoxon rank-test was used
for analyzing survival data.
RESULTS
TheAbsence of TNFRI in SCTRecipients Results in
an early Reduction of Clinical GVHD and Improved
Survival
TNF-a has been shown to be a central effector
molecule in the development of aGVHD and IPS
[14,15,17,19,20,53-55]. To ascertain whether the ef-
fects of TNF-a in each of these processes are mediated
predominantly through TNFRI or TNFRII, we
transplanted lethally irradiated wt, TNFRI2/2 or
TNFRII2/2 C57BL/6 recipient mice with bone
marrow and splenic T cells from either syngeneic B6or allogeneic LP/J donor mice as described in Mate-
rials and Methods. SCT recipients were subsequently
monitored for survival and the development of clinical
GVHD. As shown in Figure 1, severe clinical GVHD
developed in B6 wt recipients over time in comparison
to syngeneic controls (Figure 1a) and resulted in signif-
icant mortality beginning 1 week after transplant
(Figure 1b). Whereas the severity of GVHD in
TNFRII2/2 mice receiving allo-SCT did not differ
from that observed in allogeneic wt controls,
TNFRI2/2 recipients demonstrated a reduction in
clinical GVHD scores and a significant improvement
in overall survival (OS). GVHD severity was specifi-
cally decreased during the first 4 weeks after SCT
and correlated with an early reduction in mortality
(Figure 1a and b), confirming previous findings of Spe-
iser et al. [39]. To ascertain whether the survival advan-
tage observed in TNFRI2/2 recipients was in part
related to incomplete engraftment of donor cells, T
cell chimerism was assessed in surviving animals using
antibodies specific for Ly9 allelic differences between
donor and host. As shown in Figure 1c, donor T cell
engraftment after SCT was near complete andFigure 1. The absence of TNFRI in allo-SCT recipients results in an early reduction of clinical GVHD and improved survival. BM and T cells
from allogeneic, MHC matched LP/J donor mice were transplanted into wt (A, —), TNFRI2/2 (:,...), or TNFRII2/2 (,—) B6 recipients
as described in Materials and Methods. In all experiments, some B6 wt mice also received BM and T cells from syngeneic B6 donors (-, ----).
Clinical GVHD scores were determined weekly and survival was monitored daily. (A) TNFRI2/2 (:), but not TNFRII2/2 (), mice develop
significantly reduced clinical GVHD scores 7 to 28 days after allo-SCT when compared to wt controls (A). Data presented are combined from
3 comparable experiments; n 5 12 to 20 per group; *P\ .05. (B) The reduction in clinical GVHD correlates with decreased early mortality of
TNFRI2/2 recipients (...) after allo-SCT, but no difference in survival is seen between allogeneic wt (—) and TNFRII deficient (—) animals.
Data presented are combined from 4 comparable experiments; n5 21 to 38 per group; *P\ .05. (C) T cell chimerism was assessed 5 weeks after
transplant by FACS analysis for surface expression of the donor marker Ly9.1. Donor T cell engraftment after SCT was independent of the p55
or the p75 TNF receptor expression in the recipient, and comparable in all allogeneic groups. Data presented are from 1 of similar 2 experiments;
n 5 3-4 animals per group.
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dependent of TNF receptor expression in the SCT re-
cipients. Similar findings were observed in splenic T
cell populations (data not shown).
The Extent and Severity of Lung Is Significantly
Reduced in TNFRII2/2 but not in TNFRI2/2
allo-SCT Recipients
Next, we determined the severity of lung injury
in surviving mice 5 weeks after SCT. Consistent
with previous work [56], B6 recipients of syngeneic
SCT maintained normal histology, whereas wt and
TNFRI2/2 recipients of allo-SCT developed signif-
icant and comparable lung histopathology (Figure 2a).
In each group, a dense mononuclear cell infiltrate had
developed around both bronchial and vascular
Figure 2.Leukocyte infiltration into the lung is significantly reduced
in TNFRII2/2 but not TNFRI2/2 allo-SCT recipients. Animals
were transplanted as described in Figure 1 and lung injury was
assessed 5 weeks after SCT. (A, B) TNFRII2/2 ( ), but not
TNFRI2/2 ( ), recipients developed significantly less lung histo-
pathology in comparison to allogeneic wt controls (-). Syngeneic
controls maintained normal lung histology (,). (C-E) Decreased
lung histopathology scores were associated with a reduction in
BALF cellularity and BALF T cells. Data presented are combined
from 2 comparable experiments; n 5 10 to 15 per group; **P\ .01;
*P\ .05; 1P 5 .06 ( ) versus ( ).structures and was accompanied by a mixed leukocytic
infiltrate in the interstitial and alveolar spaces. These
findings were incorporated into a semiquantitative
scoring system that evaluates the severity and extent
of injury present. Using this system, lung histopathology
scores were significantly reduced in TNFRII2/2 recip-
ients (Figure 2a and b). This reduction in pulmonary pa-
thology was associated with decreases in total BALF
cellularity (Figure 2c) and BALF CD41 and CD81
T cells (Figure 2d and e), suggesting that TNFRII,
but not TNFRI, signaling plays an important role
in leukocyte infiltration into the lung following allo-
SCT.
Reduced Histopathology in TNFRII2/2 allo-SCT
Recipients Is Associated with Significantly
Decreased BALF Levels of RANTES
Recent data have shown a role for chemokines in
the development of IPS after allo-SCT [57-60]. In
addition, our group recently demonstrated that pul-
monary chemokine expression early after allo-SCT is
regulated in part by TNF-a [20]. To determine
whether the abrogation of TNF-a signaling through
TNFRII results in changes of chemokine expression
in the lung, we measured BALF of Mip-1a, RANTES,
and MCP-1 5 weeks after SCT as described in Mate-
rials and Methods. As shown in Figure 3, BALF che-
mokine levels were elevated in each scenario after
allo-SCT compared to syngeneic controls. Although
MIP-1a levels did not differ among allogeneic groups,
a significant decrease in BALF concentrations of
RANTES was observed in B6 TNFRII2/2 recipients
compared to allogeneic controls (Figure 3b), and cor-
related with reductions seen in lung histopathology
and BALF cellularity (Figure 2a-c). Decreases in
BALF MCP-1 levels were also noted TNFRII2/2
recipients and trended toward statistical significance
(Figure 3c).
Pulmonary Expression of ICAM-1 Is Reduced in
allo-SCT Recipients Deficient in TNFRII
Previous reports have indicated that pulmonary
ICAM-1 expression significantly contributes to the de-
velopment of IPS after allo-SCT [13,56], and ICAM-1
expression on ECs is dependent in part on the expres-
sion of TNFRII [43,44]. Therefore, we next deter-
mined whether differences in ICAM-1 expression
could be seen in the lungs of allogeneic wt,
TNFRI2/2 and TNFRII2/2 recipients. As shown
in Figure 4a-b, ICAM-1 was barely detectable in the
lungs of syngeneic SCT recipients compared to iso-
type control sections. Pulmonary ICAM-1 expression
was strongly increased in lungs from both wt and
TNFRI2/2 allo-SCT recipients in association with
robust cellular infiltrates seen in each group
(Figure 4c-d). ICAM-1 staining could be observed
both within the pulmonary interstitium (low power)
390 G. C. Hildebrandt et al.and along the bronchial epithelial lining (high power).
By contrast, immunohistochemical staining was re-
duced in TNFRII2/2 allo-SCT mice to a level com-
Figure 3. Reduction of leukocyte infiltration into the lungs of
TNFRII2/2 allo-SCT recipients is associated with significantly de-
creased BALF levels of RANTES. Animals received syngeneic or
allo-SCT as described in Figure 1, and BALF levels of Mip-1a,
RANTES, and MCP-1 and were determined 5 weeks later. (A-C)
BALF levels of each chemokine were increased following allo-SCT
compared to syngeneic controls (,). Although no differences in
BALF levels of Mip-1a were observed among allogeneic groups,
BALF RANTES, and MCP-1 levels were reduced in TNFRII2/2
( ) but not TNFRI2/2 ( ) recipients compared to allogeneic
controls (-). Data shown are from 1 experiment; n 5 3 to 5 per
group; *P\ .05; 1P 5 .07 ( ) versus ( ).parable to syngeneic controls (Figure 4e). In an effort
to better quantify this apparent reduction, we mea-
sured ICAM-1 expression using real-time RT-PCR
as described in Materials and Methods. As shown in
Figure 5, similar reductions in whole-lung ICAM-1
levels were noted in TNFRII2/2 recipients at the
mRNA level confirming findings obtained by immu-
nohistochemical staining. In sum, the absence of
TNFRII was associated with a reduction of ICAM-1
expression in the lung following allo-SCT consistent
with reports in other non-SCT systems.
Absence of Either the Ligand or the Receptor in
TNF-a:TNFRII Interactions Results in
a Comparable Reduction of Lung Injury after allo-
SCTacross an Isolated MHC Class I Mismatch
TNFRII is only fully activated by membrane
bound TNF-a (memTNF-a) [61], which can be used
by cytotoxic T lymphocytes (CTL) to induce target
cell lysis and apoptosis [62]. Thus, we hypothesized
that the role for TNFRII in IPS may be even more ev-
ident in a murine SCT system wherein donor and host
differ at an isolated MHC class I mismatch and the de-
velopment of acute lung injury is strictly dependent on
the recruitment of alloreactive CD81 cells to the lung.
To test this hypothesis, lethally irradiated B6 wt or B6
TNFRII2/2 recipient mice received SCT from bm1
donors and were analyzed for the development of lung
injury 5 weeks after transplant. Syngeneic B6 / B6
controls were included as negative controls. The sever-
ity of lung injury was significantly reduced in
TNFRII2/2 recipients compared to allo-SCT con-
trols as measured by lung histopathology, BALF cellu-
larity, and BALF CD81 T cells (Figure 6a-c), and was
associated with decreases in BALF levels of RANTES
that did not reach statistical significance (Figure 6d).
In a complimentary set of experiments, we tested
whether abrogation of TNF-a in donor cells results
in a reduction in lung injury similar to that observed
in allo-SCT recipients deficient in TNFRII. We
used the MHC class I mismatched strain combination
B6/ bm1 to ensure direct comparability of results. In
these experiments, lethally irradiated bm1 mice re-
ceived SCT from either syngeneic (bm1) or allogeneic
(B6 wt or B6 TNF-a2/2) donors as described in Ma-
terials and Methods, and lung injury was again assessed
at week 5 after SCT. As shown in Figure 6a, bm1 mice
receiving allo-SCT from B6 wt donors developed se-
vere lung injury compared to syngeneic controls. By
contrast, histopathology scores in bm1 animals receiv-
ing TNF-a2/2 donor cells were significantly reduced
compared to allo-SCT controls (Figure 7a) and were
comparable to those measured in B6 TNFRII2/2
animals receiving allo-SCT from bm1 donors
(Figure 6a). Consistent with previous results, observed
decreases in lung pathology were associated with
reductions in BALF cellularity, and CD81 T cells
TNFRII and Idiopathic Pneumonia Syndrome 391Figure 4. Absence of TNFRII is associated with decreased pulmonary ICAM-1 expression following allo-SCT. Animals received syngeneic or
allogeneic SCT as described in Figure 1 and the pulmonary expression of ICAM-1 was analyzed by immunohistochemistry as described in Ma-
terials and Methods. Sections shown are representative of staining observed in lungs from each group. Allogeneic wt and TNFRI2/2 recipients
(C, D) demonstrate increased signal intensity for ICAM-1 both in the interstitium and the bronchial epithelium when compared to syngeneic
SCT controls (B). By contrast, the intensity of ICAM-1 expression in lungs of TNFRII2/2 recipients is reduced (E). (900 and 400 magni-
fication; ICAM-1 brown; counterstain: hematoxylin).(Figure 7b-c). In addition, BALF TNF-a concentra-
tions were also greatly reduced to levels measured in
syngeneic controls (Figure 6e). Collectively, thesedata underscore the role of donor-derived TNF-
a and, specifically, TNFRII:TNF-a receptor:ligand
interactions in the development of IPS.
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IPS is a frequently fatal complication after allo-
SCT. The pathophysiology of IPS is complex, but
data obtained from experimental models have helped
to understand how the recruitment of cellular effectors
and the production of inflammatory cytokines contrib-
ute to lung injury [10-12,14,18-20,58-60]. With
respect to the latter, TNF-a has been specifically iden-
Figure 5.Reduction in whole-lung ICAM-1 mRNA expression con-
firms immunohistochemical staining in TNFRII2/2 recipients.
Animals received syngeneic or allogeneic SCT as described in
Figure 1 and the pulmonary expression of ICAM-1 was analyzed
by RT-PCR as described in Materials and Methods. Data are ex-
pressed as fold difference in expression compared to that observed,
in syngeneic controls. n 5 4 to 6 animals per group. *P\ .05.
Figure 6. Absence of TNFRII is associated with reduced lung injury
following allo-SCT in an isolated MHC class I mismatched system.
Lethally irradiated B6 wt and B6 TNFRII2/2 received SCT from
allogeneic bm1 donors. Syngeneic B6/ B6 controls were included
(,) and lung injury was assessed 5 weeks after SCT as described in
Materials and Methods. (A) Allogeneic TNFRII2/2 recipients
( ) demonstrate a significant reduction in lung histopathology
scores compared to allo-SCT controls (-). (B-D) Reduction in
lung histopathology in TNFRII2/2 recipients ( ) was associated
with decreased BALF cellularity, BALF CD81 T cell counts, as well
as a reduction of RANTES levels in the BALF fluid. n 5 4 to 7 per
group; **P\ .01; *P\ .05; #P\ .09.tified as a critical mediator of IPS. TNF-a levels are in-
creased in the BALF during experimental and clinical
IPS [18,63]. In addition, the neutralization of TNF-
a significantly reduces the severity of lung injury after
SCT in mice [14], and has been associated with im-
provements in pulmonary dysfunction in humans [5].
TNF-a production by donor, BM-derived, accessory
cells and mature T cells contributes to the develop-
ment of IPS [20]. However, TNF-a produced by do-
nor T cells plays a prominent role by regulating (1)
pulmonary chemokine expression early after SCT
and (2) the subsequent recruitment of donor effector
cells to the lung [20]. In this study, we investigated
whether the observed effects of TNF-a on IPS devel-
opment are mediated primarily through TNFRI and/
or TNFRII.
We have previously examined the kinetics of lung
injury using the LP / B6 system [56] and found
that histopathology scores are relatively low at 2 weeks
following allo-SCT and then increase sharply between
weeks 4 and 6. In the current studies, the severity of
systemic GVHD was comparable in each allogeneic
group at the time of analysis. We speculated that ani-
mals would continue to succumb to GVHD over
time, thereby making intergroup comparisons at later
time points more challenging, and therefore elected
to evaluate lung injury in all animals at week 5 after
SCT. Although it is possible that animals with more
Figure 7. TNFRII-mediated effects of donor-derived TNF-a are
important to the development of acute lung injury after allo-SCT.
Lethally irradiated bm 1 recipients were transplanted with BM and
T cells from either syngeneic (bm1; ,), allogeneic TNF-a1/1
B6 (-), or allogeneic TNF-a2/2 B6 donor mice ( ). Lung injury
was assessed 5 weeks after transplant. (A-C) Allogeneic transplanta-
tion with TNF-a-deficient donor cells resulted in a nearly complete
abrogation of lung histopathology associated with decreases in
BALF cellularity and CD81 T cells. (D) Although TNF-a levels
in the BALF of allogeneic recipients of TNF-a1/1 donor cells
were significantly elevated, no differences were found between
syngeneic controls and recipients after allo TNF-a2/2 SCT. All
data are from 1 of 2 comparable experiments; n 5 4 to 7 per group;
*P\ .05.
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analysis, this would be inconsistent with our previous
data and otherwise would be expected in all allogeneic
groups. Thus, although one could hypothesize that the
reduction in lung injury observed between TNFRII2/
2 and TNFRI2/2 mice could be the result of selec-
tion bias, the same argument cannot be made when
comparing TNFRII2/2 recipients to the ‘‘true’’ wt
controls. In this context, our results show that interac-
tions between TNFRII and TNF-a contribute to the
leukocyte infiltration to the lung following allo-SCT.
In fact, the reduction in lung injury in TNFRII2/2
allo-SCT recipients directly mirrors the outcome ob-
served when TNF-a2/2 mice were used as SCT do-
nors. These results are in accord with those recently
reported using a fully MHC mismatched SCT model.
Shukla and colleagues [40] demonstrated that absence
of TNFRI in allo-SCT recipients resulted in improved
early post-BMT survival that was associated with de-
creased pulmonary edema and improved lung compli-
ance on day 7 after SCT. However, cellular infiltration
into the lung along with BALF levels of pro-inflamma-
tory cytokines and chemokines were actually higher in
BALF from TNFRI2/2 SCT recipients compared
with TNFRI1/1 controls [40].
Both sTNF-a and memTNF are able to activate
TNFRI, but TNFRII can only be fully activated by
memTNF [62]. TNFRII contributes to the cytocidal
effects of TNF-a by its own signaling, and also by reg-
ulating the access of this cytokine to TNFRI, thereby
enhancing TNFRI signaling [64-68]. The absence of
either of these TNFRII functions may contribute to
the reduction in lung histopathology observed in
TNFRII2/2 recipients. However, the development of
lung injury in TNFRI2/2 recipients with a severity
and extent that is comparable to that seen in wt recip-
ients, suggests that the ‘‘ligand-passing’’ function of
TNFRII to TNFRI, or cooperative cell death signal-
ing, does not play a significant role. Rather, effects of
TNF-a:TNFRII interactions that are independent of
TNFRI appear to be operative.
Previous work has shown that lung injury is delayed
in mice lacking both TNFRI and TNFRII following
the transfer of cloned alloreactive Th1 cells [19]. In
those experiments, sTNF-a is secreted by both Th1
cells and host macrophages, and leads to perivascular
infiltration, interstitial pneumonitis, and vascular in-
jury [19]. Cytotoxic CD81 T cells are not involved in
the pathophysiology of lung injury in that model, and
no cytolytic potential was seen for the CD41 T cells
transfused [19]. It is likely that TNF-a-mediated ef-
fects in that model are propagated through TNFRI,
and the delayed presence of pulmonary injury in the
absence of TNFRI and TNFRII involves other inflam-
matory cytokines including IFN-g or IL-1. In contrast,
the recruitment of donor CD81 T cells plays a critical
role in murine models of lung injury after allo-SCTincluding the ones used in this study [50,60]. Both
CD41 and CD81T cells have been shown to contribute
to systemic GVHD when LP mice are used as donors
for irradiated B6 recipients [69], whereas GVHD de-
velops almost exclusively in response to CD81 activa-
tion in the BM1/ B6 model because of an isolated
class I MHC mismatch that exists between these 2
mouse strains [60]. CD81 T cells predominantly ex-
press memTNF-a [70], and may initiate injury via di-
rect cytotoxic effects on alveolar epithelial cells,
which are also uniquely sensitive to memTNF-a-me-
diated injury [71].
Antigen recognition on alveolar epithelial cells by
antigen-specific CD81 T cells has been shown to re-
sult in epithelial cell activation, inflammatory chemo-
kine induction, and cytolysis through memTNF-
a [71]. This CD81 T cell-mediated lung injury occurs
in the absence of perforin and Fas, and is completely
abrogated by neutralizing TNF-a [72]. TNF-a neu-
tralization is also associated with a reduction of both
experimental and clinical lung injury after allo-SCT
[5,14], suggesting therefore, that similar mechanisms
may be used by alloantigen-specific CTLs that con-
tribute to pulmonary damage after allo-SCT.
We and others have shown that TNFRI:TNF-
a receptor:ligand interactions contribute to the toxic-
ity incurred early after allo-SCT [39]. TNFRI is
known as the high affinity receptor for sTNF-a and
sTNF-a production is directly related to inflammation
engendered by pretransplant conditioning and donor
T cell activation and expansion early after allo-SCT.
However, a role for TNFRII in leukocyte infiltration
into inflamed tissues is supported by both experimen-
tal and clinical data. Upregulation of TNFRII, but not
TNFRI, has been observed in pulmonary microvascu-
lar ECs from patients with ARDS, and is associated
with increases in CD14, ICAM-1, and VCAM-1 ex-
pression in this context [43]. Similar findings were re-
ported in a murine model of cerebral malaria where
ICAM-1 and TNFRII, but not TNFRI, expression
are significantly increased in brain microvasculature
[44]. Mice lacking TNFRII2/2, but not TNFRI2/2,
were resistant to mortality caused by this infection
[44]. Interestingly, ICAM-1 upregulation was not de-
tected in the brain of TNFRII2/2 mice, indicating
a close correlation between TNFRII, ICAM-1, and
disease development [44]. Our group recently con-
firmed and extended the findings by Panoskaltsis-Mor-
tari and coworkers, and demonstrated a role for
ICAM-1 expression on pulmonary vascular ECs in
the development of IPS [13,61]. In the current study,
we show for the first time a potential association be-
tween TNFRII, ICAM-1 expression and pulmonary
disease after allo-SCT. ICAM-1 expression was de-
creased in TNFRII2/2 recipients after allo-SCT
within the alveolar wall, which most likely reflects de-
creased ICAM-1 on alveolar epithelial cells and the
394 G. C. Hildebrandt et al.alveolar capillary endothelium. Reductions in protein
expression in TNFRII2/2 allo-SCT recipients as as-
sessed by immunohistochemical staining are sup-
ported by similar reductions in whole-lung mRNA
levels (Figure 5). Therefore, the observed reduction
in lung injury in TNFRII2/2 recipients in this study
may not only involve the lack of TNFRII-mediated
cell death, but also result from a decreased expression
of adhesion molecules like ICAM-1.
Finally, reduced lung histopathology in
TNFRII2/2 recipients shown in this study was also
associated with decreased RANTES levels in the
BALF. We have recently shown that donor T cell-
derived RANTES contributes in part to leukocyte re-
cruitment to the lung following SCT [59]. However,
chemokine production by nonhematopoietic cells in
the lung may also be influenced by TNF-a:TNFRII
interactions, as we recently demonstrated a regulatory
role of donor T cell TNF-a in pulmonary chemokine
expression during IPS [20]. Therefore, it remains un-
resolved whether the reduction in BALF RANTES
levels in TNFRII2/2 allo-SCT recipients is second-
ary to a decreased number of infiltrating donor T cells,
a reduction of RANTES secretion because of abroga-
tion of TNF-a:TNFRII signaling, or both.
Taken together, our data demonstrate a role for
TNFRII in the inflammation engendered during the
development of IPS, and suggest a link between
TNF-a:TNFRII signaling, ICAM expression, and
leukocyte infiltration to the lung that occurs in this
context. Clinically, IPS develops during the adminis-
tration of systemic immunosuppression and is poorly
responsive to the addition of conventional anti-inflam-
matory therapy. Thus, a better understanding of the
mechanisms involved in lung injury following allo-
SCT is essential to improving outcomes of this fre-
quently fatal complication. To this end, our data
further support the use of novel approaches targeting
TNF-a:TNFRII receptor:ligand interactions in addi-
tion to standard immunosuppressive therapy to treat
or prevent IPS after allo-SCT.
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